Drugs / NY-ESO-1 ISCOMATRIX® vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00518206 | Nov 2003 → Jan 2010 | melanoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 ISCOMATRIX vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00518206 ↗ |
| Modality | Vaccine | “We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISCOMATRIX adjuvant” PMID 19276262 ↗ Mar 2009 |